Seres Therapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $351 | $0 | $0 | $5,958 |
Gross Profit | -13,001 | -1,059 | -3,527 | 2,979 |
EBITDA | 9,263 | -18,796 | 33,758 | -14,552 |
EBIT | 8,204 | -19,855 | 32,682 | -15,637 |
Net Income | 8,204 | -19,855 | 32,682 | -15,637 |
Net Change In Cash | 351 | 0 | 0 | 5,958 |
Free Cash Flow | 2,198 | -13,470 | 26,876 | -38,972 |
Cash | 47,638 | 45,379 | 58,849 | 30,793 |
Basic Shares | 8,771 | 8,743 | 8,714 | 8,650 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $126,325 | $7,128 | $144,927 |
Gross Profit | -3,532 | 125,621 | 6,124 | 144,927 |
EBITDA | -120,303 | -181,419 | -170,932 | -56,721 |
EBIT | -125,771 | -187,662 | -177,561 | -62,668 |
Net Income | 136 | -113,724 | -250,157 | -65,578 |
Net Change In Cash | 0 | 126,325 | 7,128 | 144,927 |
Cost of Revenue | -16,786 | 71,954 | ||
Free Cash Flow | -148,989 | -125,329 | -238,637 | -2,878 |
Cash | 30,793 | 127,965 | 163,030 | 180,002 |
Basic Shares | 7,770 | 6,400 | 5,403 | 4,585 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0.94 |
2025-06-30 | -$2.27 |
2025-03-31 | -$2.23 |
2024-12-31 | -$0.11 |
